Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ceivables, net (including unbilled receivables)2,343,9874,317,170Prepaid expenses and other current assets470,6661,014,002Assets held for sale976,6001,000,100Total current assets18,337,03023,583,729Property and equipment, net900,9261,178,416Other long-term assets and deferred costs53,38488,447Goodwill2,348,4532,348,453Total assets$

21,639,793$

27,199,045LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

445,515$

3,128,203Accrued expenses and other liabilities3,245,9903,035,284Total current liabilities3,691,5056,163,487Other long-term liabilities454,093461,858Derivative instruments2,956,0808,362,995Total liabilities7,101,67814,988,340Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,194,035 and 46,238,244 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively4,8194,624Additional paid-in-capital207,810,326200,847,468Accumulated other comprehensive income1,161,6201,250,497Accumulated deficit(194,438,650)(189,891,884)Total stockholders'
equity14,538,11512,210,705Total liabilities and stockholders' equity$

21,639,793$

27,199,045PHARMATHENE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months endedSeptember 30,Nine months endedSeptember 30,2011201020112010Contract revenue$

5,260,057$

6,243,567$

18,026,619$

14,139,711Operating expenses:Research and development4,884,2316,172,14716,688,70317,064,900General and administrative3,283,2463,177,88811,632,27212,625,132Depreciation and amortization114,494258,231348,813757,929Total operating expenses8,281,9719,608,26628,669,78830,447,961Loss from operations(3,021,914)(3,364,699)(10,643,169)(16,308,250)Other income (expenses):Interest income3,96118410,4966,249Interest expense(9,932)(946,023)(40,540)(2,815,638)Other income (expense)95,520(93,260)50,89275,914Change in market value of derivative instruments2,898,86975,5946
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... HORSHAM, Pa. , Oct. 27, 2014 /PRNewswire/ ... Colitis Foundation of America (CCFA) announced today the ... , an educational campaign designed ... bowel diseases (IBD) on the paired role of ... To view the multimedia assets associated with ...
(Date:10/26/2014)... The report "Protective Coatings Market by ... Trends & Forecast to 2019", defines and segments the ... volume consumed and value generated. The protective coatings consumption ... to 6,701.3 KT by 2019, at a CAGR of ... data tables and 22 figures spread through 219 slides ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... provided people with many items such as iPods, ... audio capabilities. Technology is evolving so quickly that ... years ago are now taken for granted. , ... understand how technology may evolve when entering into ...
... series of articles on raising capital from investors. This installment focuses ... time when raising equity capital, the offering terms are summarized in ... When dealing with angel investors , it is typical for ... angel investors will want to negotiate the initial term sheet, especially ...
... . - Oren Harari is coming to Milwaukee next ... of innovation. , ,Not just to manufacturers, who he will be ... to business organizations in a number of sectors, including technology. , ... to Compete in a Copycat Economy , he intends to deploy ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 2Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 3
(Date:10/29/2014)... kind of stem cell, those referred to as ,facultative, ... is apparently nothing that differentiates these cells from the ... they retain the capacity to become stem cells again. ... an organ that hosts cells that stimulate tissue growth, ... case of a transplant. Knowledge of the underlying ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
Breaking Biology News(10 mins):A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Kidney cancer in Central Europe 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... days over what they eat, and whether horse meat ... been dominating headlines globally - calling for new ... successful food identification and authentication. As companies and manufacturers ... the gullible public, it is estimated that up to ...
... 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and ... build a pipeline of therapeutic drugs aimed at ... needs. Under this agreement, Mayo Clinic scientists will ... for Chemical Genomics (Prebys Center) to conduct early-stage ...
... increasingly resembles lusher latitudes to the south, according to ... land surface and newly improved satellite data sets. ... the relationship between changes in surface temperature and vegetation ... Ocean. Results show temperature and vegetation growth at northern ...
Cached Biology News:DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement 2Amplified greenhouse effect shifts north's growing seasons 2Amplified greenhouse effect shifts north's growing seasons 3
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Homo sapiens formin-like...
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: